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Abstract: This paper highlights the importance of lipid-based colloidal carriers and their 
pharmaceutical implications in the delivery of peptides and proteins for oral and parenteral 
administration. There are several examples of biomacromolecules used nowadays in the 
therapeutics, which are promising candidates to be delivered by means of liposomes and lipid 
nanoparticles, such as solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC). 
Several production procedures can be applied to achieve a high association efﬁ  ciency between 
the bioactives and the carrier, depending on the physicochemical properties of both, as well as on 
the production procedure applied. Generally, this can lead to improved bioavailability, or in case 
of oral administration a more consistent temporal proﬁ  le of absorption from the gastrointestinal 
tract. Advantages and drawbacks of such colloidal carriers are also pointed out. This article 
describes strategies used for formulation of peptides and proteins, methods used for assessment 
of association efﬁ  ciency and practical considerations regarding the toxicological concerns.
Keywords: peptides, proteins, liposomes, solid lipid nanoparticles, SLN, nanostructured lipid 
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Introduction
In the last decades, several new pharmaceutically active peptides and proteins have 
been developed as a consequence of the progress of biotechnological techniques and 
genetic engineering. These new therapeutic biomolecules are usually characterized 
by a large size, short plasma half-life, high elimination rate (easy to be degraded 
by enzymatic and body ﬂ  uids), limited ability to cross cell membranes, and poor 
bioavailability through intestinal administration. Therefore, frequent injection of drug 
over a long therapeutic period, are generally required when such biomolecules are 
used for therapeutic purposes (Hu et al 2004).
Traditional administration routes for these drugs are the oral and parenteral 
administration. The orally administered drug is absorbed from the gut and enters the 
blood stream, diffuses from the enteral absorption sites to blood and tissue, whereas 
a parenterally administered drug is injected directly into the blood, which is typically 
only possible in form of a drug solution or emulsion. After administration, the drug 
will be present as molecules in solution (ie, blood). It distributes in the body according 
to its physicochemical properties, eg, its partitioning coefﬁ  cient. The presence as 
molecular solution turns these molecules easily accessible to degrading factors (eg, 
water, enzymes), and then they cannot be directed (targeted) to their desired site 
of action. One approach to overcome these problems would be the entrapment of 
those drugs into a particulate carrier system. Incorporation will protect them against 
degradation in vitro and in vivo, the release rate can be modiﬁ  ed, offering as well 
targeting approaches. Examples of such particulate carrier systems are the polymeric 
nanoparticles (Speiser 1973; Kreuter 1978; Marty et al 1978; Couvreur et al 1979; International Journal of Nanomedicine 2007:2(4) 596
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Luck et al 1998), microemulsions (Bangham 1993), 
liposomes (Bangham 1993), solid lipid nanoparticles (SLN) 
(Morel et al 1996; Almeida et al 1997; García-Fuentes et al 
2002; Muller et al 2002a, 2006; Ugazio et al 2002; Gualbert 
et al 2003; Carsten et al 2004; Hu et al 2004; Garcia-Fuentes, 
Prego et al 2005; Garcia-Fuentes, Torres et al 2005; Schubert 
and Muller-Goymann 2005; Pedersen et al 2006; Souto and 
Muller 2006; Trotta et al 2006; Zhang et al 2006), nanostruc-
tured lipid carriers (NLC) (Muller et al 2002a; Garcia-Fuentes, 
Prego, et al 2005; Garcia-Fuentes, Torres, et al 2005) and 
self-emulsiﬁ  ed drug delivery systems (SEDDS) (Gursoy and 
Benita 2004; Robert 2004; Zheng and Fulu 2006). Despite 
being a very smart idea, examples of such concept never 
reached the pharmaceutical market. It has been tried with 
polymeric nanoparticles, nevertheless, reasons for this are 
the regulatory issues and the scaling up problems. In fact, 
polymers used (eg, polylactic acid (PLA) and its co-polymer 
with glycolic acid (PLGA) (Luck et al 1998)) are accepted 
by the regulatory authorities for parenteral administration as 
implants (eg, Zoladex®) and microparticles (eg, Decapeptyl®, 
Parlodel LA®, Enantone Depot®), but not in the nanoparticulate 
form. In contrast to microparticles, the nanoparticles can be 
internalized (phagocytosed) by cells, intracellular degradation 
can cause cytotoxic effects. In addition, there is a lack of large 
scale production methods (Muller and Keck 2004).
Various approaches have been examined to overcome 
the delivery problems of peptides and proteins by means of 
colloidal carriers. The use of the above-mentioned lipid-based 
carrier systems seems to be promising.
Microemulsions are thermodynamically stable isotropic 
dispersions, transparent, of low viscosity, consisting of oil and 
water stabilized by an interfacial ﬁ  lm of surfactant molecules, 
typically in conjunction with a co-surfactant . Usually, the inner 
phase either oil (o/w emulsions) or water (w/o emulsions) has 
sizes ranging from 5 to 100 nm. Microemulsions (o/w and 
w/o) have been proposed to enhance the oral bioavailability of 
drugs, including peptides. Hydrophilic drugs of this kind can be 
successfully incorporated into the dispersed aqueous phase of 
w/o microemulsion droplets where it affords some protection 
against enzymatic degradation when administered orally. 
Sandimmune Neoral®, an example of a marketed formulation, 
is a microemulsion pre-concentrate containing a surfactant, 
lipophilic and hydrophilic solvents and ethanol. The presence 
of a surfactant and in some case a co-surfactant, and medium 
chain diacylglycerols is related in many cases, to the increase 
of membrane permeability, thereby increasing the drug uptake. 
Recently, considerable dosage form development activity has 
focused on the formulation of lecithin-based microemulsions. 
Lecithin is a naturally occurring, non-toxic and safe material. 
It is also a biological surfactant and a major component of 
membrane lipids (Cilek et al 2005).
Lipid nanoemulsions are ﬁ  ne o/w dispersions, having 
droplets covering the size range between 50 and 200 nm. Nano-
emulsions are also referred as mini-emulsions (Bouchemal 
et al 2004). Nanoemulsions were introduced during the 50ies 
for the purpose of parenteral nutrition. Fatty vegetable oils 
(eg, soy oil) or middle chain triacylglycerols are used as lipid 
phase, being typically 10%–20% of the emulsion. Further 
ingredients include phospholipids (stabilizers, 0.6%–1.5%) 
and glycerol (osmolarity regulation, 2.25%). During recent 
years it has been recognized that these systems might also 
be used as drug carriers for lipophilic drugs and several for-
mulations are nowadays commercialized. Examples include 
etomidate (Etomidat-Lipuro®) and diazepam (Diazepam-
Lipuro®). In comparison to previous solubilization-based 
formulations of these drugs, a reduction of the local and 
systemic side effects (eg, pain during injection) has been 
found. The hemolytic activity of sodium oleate is decreased 
in lipid emulsions because the lytic agent is restricted at 
the interface and in the lipophilic core, and thus the direct 
contact with erythrocyte membranes is hindered (Jumaa and 
Muller 2000). However, an important drawback related to 
nanoemulsions is the limited controlled release properties, 
due to the small size and the liquid state of the carrier. For 
most drugs, a rapid release will be observed. It has been 
estimated, that retarded drug release requires very lipophilic 
drugs, ie, the Ko/w should be larger than 106:1. Advantages 
of nanoemulsions include toxicological safety and a high 
content of the lipid phase, as well as the possibility of large 
scale production by high pressure homogenization (Mehnert 
and Mader 2001).
Peptides and proteins associated to microemulsions and 
nanonoemulsions are, for example, cyclosporine A (Robert 
2004), immunoglobulin G (Gerhardt and Dungan 2002; 
Flanagan and Singh 2006), insulin (Watnasirichaikul et al 
2000; Watnasirichaikul et al 2002; Cilek et al 2005, 2006),   
α-lactalbumin (Rohloff et al 2003; Flanagan and Singh 2006) 
and fusion protein vaccine (Ge et al 2006).
Particular examples of nanoemulsions are the SEDDS, 
defined as isotropic mixtures of an oil, surfactant, co-
surfactant and drug (Constantinides 1995; Gursoy and Benita 
2004). These components form ﬁ  ne o/w nanoemulsions 
when introduced into aqueous media under mild agitation. 
The digestive motility of the stomach and intestine provides 
the agitation required for self-emulsiﬁ  cation in vivo. Factors 
controlling the in vivo performance of SEDDS include their International Journal of Nanomedicine 2007:2(4) 597
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ability to form small droplets of oil and the polarity of the 
oil droplets to promote faster drug release into the aqueous 
phase. The smaller oil droplets provide a large interfacial 
area for pancreatic lipase to hydrolyze triacylglycerols and 
thereby to promote the rapid release of the drug and/or 
formation of mixed micelles of the bile salts containing the 
drug. The surfactants used in these formulations are known 
to improve the bioavailability by various mechanisms includ-
ing: (i) improved drug dissolution (Constantinides 1995), 
(ii) increased intestinal epithelial permeability (Swenson 
and Curatolo 1992), (iii) increased tight junction perme-
ability (Lindmark et al 1995), and (iv) decreased/inhibited 
P-glycoprotein drug efﬂ  ux (Yu et al 1999). A marketed 
formulation of cyclosporine (Sandimmune Neoral®), a micro-
emulsion pre-concentrate with self-emulsifying properties, is 
reported to improve oral bioavailability and reduce inter- and 
intra-subject variability in cyclosporine pharmacokinetics. A 
few other studies have reported enhancement in the bioavail-
ability of poorly soluble drugs when formulated as SEDDS 
(Kommuru et al 2001; Gursoy and Benita 2004). Since a rela-
tively high concentration of surfactants is generally employed 
in the SEDDS formulation, toxicity of the surfactant being 
used should be taken into account. In fact, a compromise 
must be reached between the toxicity and self-emulsiﬁ  cation 
ability of the surfactant that is considered for use. Currently, 
several formulations have been developed to produce modi-
ﬁ  ed emulsiﬁ  ed formulations as alternative to conventional 
SEDDS. These include, for example, self-microemulsion 
formulations (Vondercher and Meizner 1994), surfactant dis-
persions (Aungustan et al 1994), pre-formulated freeze-dried 
emulsions (Tsuji et al 1996), microencapsulated emulsions 
(Jizomoto et al 1993), lipid/cross-linked polymeric matrices 
(Boltri et al 1997), self-emulsiﬁ  able pellets (Newton et al 
2001), and solid self-emulsifying systems (self-emulsifying 
tablets) (Attama et al 2003). SEDDS typically produce emul-
sions with a droplet size between 100 and 300 nm, while 
self-microemulsifying drug delivery system (SMEDDS) 
form transparent microemulsions with a droplet size of less 
than 50 nm. When compared to emulsions, which are sensi-
tive and metastable dispersed forms, SEDDS are physically 
stable formulations that are easy to manufacture. Thus, for 
lipophilic drug compounds that exhibit a dissolution rate 
limited absorption, these systems may offer an improve-
ment in the rate and extent of absorption and result in more 
reproducible blood/time proﬁ  les (Gursoy and Benita 2004). 
In order to produce peptides- or proteins-loaded SEDDS, 
these bioactives are ﬁ  rst formulated in a w/o microemulsion 
pre-concentrate, and then dispersed into an aqueous phase to 
form a w/o/w microemulsion prior to administration (Zheng 
and Fulu 2006). The few commercial products related to these 
formulations are actually nonaqueous microemulsions, also 
known as microemulsion pre-concentrate, where the polar 
solvent is ethanol and not water. Upon contact with aqueous 
media, such as gastrointestinal fluids, the nonaqueous 
microemulsion spontaneously forms a ﬁ  ne dispersion or 
aqueous microemulsion (Robert 2004). Examples of peptides 
and proteins associated to SEDDS intended for oral admin-
istration are the cyclosporine A (Gursoy and Benita 2004; 
Robert 2004) and leuprolide (Zheng and Fulu 2006).
Liposomes are spherical vesicles composed of one or more 
phospholipid bilayers (in most cases phosphatidylcholine). 
Lipophilic drugs can be incorporated within the lipid bilayers 
while hydrophilic drugs are solubilized in the inner aqueous 
core (Gregoriades et al 1993). Drug release, in vivo stability, 
and biodistribution, are determined by the size of the vesicles, 
their surface charge, surface hydrophobicity, and membrane 
ﬂ  uidity (Senior 1987). Membrane permeability can be adapted 
by the selection of the phospholipids composition, and by 
the presence of additives, such as cholesterol molecules. It is 
possible to avoid a rapid reticuloendothelial uptake of the lipo-
somes by the incorporation of natural compounds (eg, ganglio-
sides) or by the use of chemical modiﬁ  ed polyethylene glycols 
(PEG′s) (Gabizon et al 1994). The development of such 
sterically stabilized systems (‘stealth liposomes’) allows the 
development of drug targeting strategies (eg, by incorporation 
of speciﬁ  c antibodies) (Martin and Papahadjopoulos 1982). 
Liposomes also allow the intravenous injection of lipophilic 
drugs with very low water solubility, eg, amphotericin B 
(AmBisome®) (Janknecht et al 1992), reducing therefore 
the toxicity of such drugs. However, chemical and physical 
stability problems have been described leading to liposome 
aggregation and drug degradation during storage, compromis-
ing therefore the performance of liposome as intravenous drug 
carriers (Couvreur et al 1995; Mehnert and Mader 2001).
Nanoparticles based on solid lipids (SLN, NLC) have been 
proposed as an alternative colloidal drug delivery system to 
polymeric nanoparticles, emulsions and liposomes (Muller, 
Lippacher et al 2000; Muller, Mader et al 2000). They are 
composed of solid lipids stabilized with an emulsifying layer 
in an aqueous dispersion, ie, they resemble the nanoemulsions 
by replacing the inner liquid lipid with a solid lipid. The 
use of solid lipids instead of oils is a very attractive idea to 
achieve controlled drug release, because drug mobility in 
a solid lipid should be considerably lower compared with 
an oily phase. SLN are composed of solid lipids and show 
a submicron colloidal size between 50 and 1000 (Muller, International Journal of Nanomedicine 2007:2(4) 598
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Dingler et al 1997; Muller, Weyhers et al 1997). Advantages 
of such carriers include the composition (physiological 
compounds), the fast and effective production process, 
including the possibility of large scale production, the avoid-
ance of organic solvents in the production procedures, and the 
possibility to produce high concentrated lipid suspensions. 
Disadvantages include low drug loading capacities (the drug 
loading capacity of conventional SLN is limited because 
of the formation of a perfect lipid crystal matrix) (Wissing 
et al 2004), the presence of alternative colloidal structures 
(micelles, liposomes, mixed micelles, drug nanocrystals) in 
the aqueous dispersion, the complexity of the physical state 
of the lipid (transformation between different modiﬁ  ca-
tions, possibility of supercooled melts) which cause stabil-
ity problems during storage or administration (eg, gelation, 
particle size increase, drug expulsion). Sample dilution or 
water removal might signiﬁ  cantly change the equilibrium 
between the different colloidal species and the physical 
state of the lipid (Mehnert and Mader 2001). The solid core 
contains drug dissolved or dispersed in the high melting 
fat solid matrix. The hydrophobic chains of phospholipids 
are embedded in the fat matrix. Depending on the type and 
concentration of the lipid, 0.5 to 5% emulsiﬁ  er (surfactant) 
is added for the physical stabilization of the system (Mehnert 
and Mader 2001). In particular, poloxamer 188, polysorbate 
80, lecithin, polyglycerol methylgluco distearate, sodium 
cocoamphoacetate or saccharose fatty acid esters are very 
often employed.
The second generation of lipid nanoparticles has been 
introduced with the NLC (Luck et al 1998; Muller and 
Dingler 1998). These particles are prepared not from solid 
lipids only but from a blend of a solid lipid with a liquid 
lipid (oils) in such a proportion that the mixture needs to be 
solid at least at 40 ºC. Advantages of this delivery system 
are the accommodation of higher amounts of drugs due 
to the formation of a less ordered lipid matrix with many 
imperfections (Muller et al 2002a, 2002b, 2004; Muller and 
Wissing 2003). The lipid matrix gives more ﬂ  exibility for 
modulation of drug release, increasing the drug loading and 
preventing its leakage.
Similarly to polymeric nanoparticles, the solid matrix 
of SLN and NLC protects the incorporated drugs against 
chemical degradation, allowing the modulation of release 
proﬁ  les. Lipid nanoparticles have been tested for several 
administration routes (Mehnert and Mader 2001), such as oral 
and peroral (Yang et al 1999), pulmonary, ocular (Muller et al 
2004), topical, dermal and transdermal administration (Souto 
et al 2004a, 2004b), as well as for gene therapy (Tabatt et al 
2004), as new adjuvants for vaccines (Olbrich et al 2002), 
and for parenteral delivery. Lipid nanoparticles of suitable 
composition have been shown to be well tolerated in vitro, as 
well as after bolus injection into mice and rats (Olbrich et al 
2001). Nanoparticles can accumulate in target tissues based 
on their natural host cell tropisms and on their biophysical 
properties (passive targeting). In practice, active targeting to 
cells other than the mononuclear phagocytic system (MPS) 
cells is often insufﬁ  cient for rapid and speciﬁ  c accumulation 
in target tissues. Further improvement of tissue selectivity 
can be achieved by engineering the surface of lipid carriers 
with hydrophilic polymers (Goppert and Muller 2003; 
Göppert and Müller 2004) or coupling targeting ligands 
(Muller et al 2005). Lipid nanoparticles have been coated 
with PEG or chitosan, in order to be able to enter the Caco-2 
cell monolayers (Garcia-Fuentes, Prego et al 2005).
The delivery of peptides and proteins intended for 
therapeutic purposes might cause special difficulties 
regarding their encapsulation, especially because most of 
them have a signiﬁ  cant hydrophobic component and thus 
show a tendency to adsorb onto surfaces, such as glass and 
plastic. Such adsorption behavior can lead to distinct losses in 
the amount of macromolecule available for delivery (Duncan 
et al 1995). Furthermore, the amount of peptide or protein 
to be incorporated within the system is dependent on their 
physicochemical properties and on the production procedure 
(Hu et al 2004). The present review describes in detail the 
use of colloidal carriers composed of lipid materials for the 
delivery of peptides and proteins, particularly for oral and 
parenteral administration.
State of the art in peptide and 
protein delivery
The convenience and acceptability of the oral route for drug 
administration means that it has received much attention for 
the delivery of macromolecules, such as peptides and proteins. 
It has already been shown that the nanoencapsulation of 
biomacromolecules in colloidal particles protects them 
against the harsh environment of the gastrointestinal tract, 
and enhances their transmucosal transport (Mathiowitz et al 
1997; Tobío et al 1998). This ability of the colloidal carriers 
to enhance the transport of the associated macromolecules 
has been attributed to different mechanisms depending 
on the nanocarrier composition. These mechanisms are 
(Garcia-Fuentes, Prego et al 2005): (i) mucoadhesion, (ii) 
particle internalization phenomenon, and (iii) permeation 
enhancing effect. Various approaches have been used in 
an attempt to overcome these barriers and to increase the International Journal of Nanomedicine 2007:2(4) 599
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oral bioavailability of such bioactives including the use 
of polymeric particulates. The encapsulation within such 
particulate delivery systems can protect peptides and proteins 
from proteolytic enzymes. Moreover, if the size of the 
particles is sufﬁ  ciently small (<1 μm), they may pass across 
the intestinal mucosa and thus facilitate the absorption of the 
bioactive drugs from the gut lumen (Watnasirichaikul et al 
2000). Hydrophobic nanoparticles are preferentially trans-
ported through the gut associated lymphoid tissue, whereas 
particles with a more hydrophilic nature are transported 
across the regular enterocytes (Garcia-Fuentes, Prego et al 
2005). Under such circumstances, the material used for the 
preparation of the particulate carrier must be biodegradable 
(Watnasirichaikul et al 2000). Examples of biocompatible 
and physiological materials are the lipids used for the produc-
tion of lipid-based colloidal carriers. Hydrophilic polymers 
such as polyacrylate derivatives and chitosan are examples 
of mucoadhesive materials used to coat these colloidal car-
riers. Regarding parenteral administration, macromolecules 
have been delivered by means of fat emulsions and liposomes 
(Robert 2004). In the 60ies, the ﬁ  rst safe parenteral fat emul-
sion (Intralipid®) was developed by Wretlind for parenteral 
nutrition (Muller et al 1993; Muller and Heinemann 1994a, 
1994b). This was the beginning of a new delivery system 
for lipophilic drugs, which can be incorporated easily into 
the oil droplets. Other interesting parenteral carrier systems 
are the liposomes. Major obstacles for the development of 
liposomal formulations intended for parenteral drug delivery, 
are the limited physical stability of the dispersions, drug 
leakage, low activity due to no speciﬁ  c tumor targeting, non 
speciﬁ  c clearance by the (MPS) and difﬁ  culties in scaling 
up the production procedure (Arulsudar et al 2004; Tabatt 
et al 2004).
Lipid-based colloidal carriers
Liposomes
Liposomes are concentric bilayered vesicles in which an aque-
ous volume is entirely enclosed by a membranous lipid bilayer 
mainly composed of natural or synthetic phospholipids. 
Liposomes are formed when thin lipid ﬁ  lms or lipid cakes 
are hydrated and stacks of liquid crystalline bilayers become 
ﬂ  uid and swell. During stirring, hydrated lipid sheets detach 
and self associate to form vesicles, which prevent interac-
tion of water with the hydrocarbon core of the bilayer at 
the edges. Depending on the method of preparation, lipid 
vesicles can be multi-, oligo- or unilamellar, containing many, 
a few, or one bilayer shell(s), respectively. The diameter of 
the lipid vesicles may vary between about 20 nm and a few 
hundred micrometers (Walde and Ichikawa 2001). Small 
unilamellar vesicles (SUVs) are surrounded by single lipid 
layer (25–50 nm), whereas several lipid layers separated 
by intermittent aqueous layer surround large unilamellar 
vesicles (LUV) (100–200 μm). Giant unilamellar vesicles 
(GUV) have a mean diameter of 1–2 μm, multilamellar 
vesicles (MLV) have a mean diameter between 1 μm and 2 
μm (10 layers). Multivesicular vesicles are liposomes with 
lots of vesicles inside. Liposomes are characterized in terms 
of size, surface charge and number of bilayers (Walde and 
Ichikawa 2001).
Enveloped viruses, such as influenza or HIV, carry 
fusogenic proteins on their surface by which they enter the 
host cell (Torchilin et al 2001). Membrane destabilization 
and fusion is accomplished by a short amphiphilic sequence, 
the fusion peptide, located either at the top or in an internal 
region of the protein, which gets exposed upon receptor 
recognition or at acid pH upon endocytosis. Anchoring the 
peptide to the lipid bilayer via a myristic chain was shown 
to greatly enhance the fusogenic action and may provide a 
convenient way of incorporating the peptides into vesicular 
carriers.
An alternative, more cost-effective and less immunogenic 
approach relies on the adsorption of pH-titrable polymers 
to the liposomal surface. Poly-histidine and poly  lysine, for 
example, become positively charged upon lowering the pH and 
have been shown to destabilize and fuse negatively charged 
membranes in vitro. Polyanions, bearing carboxyl groups, are 
useful for destabilizing and fusing both negatively charged 
as well as uncharged membranes, due to their hydrophobic 
character at low pH. Promising pH-sensitive polyanions are, 
for example, poly(acrylic acid) derivatives and succinylated 
poly(glycerol)s. Altogether, there remains much potential to 
be explored with synthetic polymers and many open questions 
concerning their behavior in combination with liposomal 
carriers in vivo (Anne 2002). Peptides and proteins associated 
to liposomes are summarized in Table 1.
The methods below have been used for the encapsula-
tion of peptides and proteins in liposomes. If natural or 
synthetic long-tailed phospholipids are dispersed in aque-
ous solution they form large liposomes, ie, multilamellar 
vesicles (MLV). Several methods have been developed to 
form unilamellar vesicles from multi-bilayers (Segota and 
Tezak 2006).
In the dry lipid hydration method, the vesicle-forming 
amphiphiles are ﬁ  rst dissolved in an organic solvent (often 
chloroform) and the solvent is completely removed by 
rotatory evaporation and high vacuum drying in a round International Journal of Nanomedicine 2007:2(4) 600
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bottom ﬂ  ask. In this way, a thin, dry lipid ﬁ  lm is formed 
at the inner surface of the ﬂ  ask walls, to which an aqueous 
solution containing the peptide or protein to be entrapped 
is added. Vigorous shaking with the help of a vortex mixer 
above the phase transition temperature (Tm) of the lipids 
leads to a dispersion of the lipid multi-layers in the aqueous 
solution, which results in the formation of a heterogeneous 
population of liposomes. The resulting size distribution 
and lamellarity of the MLV is highly heterogeneous, but 
sophisticated procedures have been developed to produce 
uniformly sized liposomes (Frkanec et al 2003; Takeuchi 
et al 2003; Takeuchi et al 2005; Thongborisute et al 2006; 
Brgles et al in press).
With the extrusion method, a controlled reduction in size 
and lamellarity of MLV can be achieved by using track-etch 
polycarbonate ﬁ  lters which contain almost cylindrical pores 
of a deﬁ  ned size. The MLV suspension is passed under mod-
erate pressure repetitively (usually 10 times) through these 
ﬁ  lters above the Tm which leads to a mechanical transforma-
tion of the large vesicles into smaller ones. Usually, all the 
extrusion is started with ﬁ  lters containing relatively large 
pores (mean diameter, eg, 400 nm), followed by a ﬁ  ltration 
through smaller pores (200 nm and often ﬁ  nally 100 nm) 
(Torchilin et al 2001; Visser et al 2005).
With the freezing and thawing method, upon repetitively 
freezing the MLV suspension in liquid nitrogen (at −195 °C), 
Table 1 Examples of peptides and proteins associated to liposomes, the production procedure and the association efﬁ  ciency
Protein/peptide  Production  procedure  Association  References
   efﬁ  ciency (%)
Adamantyltripeptides  Dry lipid hydration  -  (Frkanec et al 2003)
Anti-ovalbumin antibodies  Dry lipid hydration  -  (Brgles et al in press)
Basic ﬁ  broblaste growth factor  Freeze-thawing extrusion  75–80  (Plum et al 2000; Luo et al 2003)
Bovine serum albumin  Reversal evaporation  25–71  (Dai et al 2005, 2006;
 Double  emulsiﬁ  cation  43–71  Murakami et al 2006)
 Freeze-thawing  20–45
Calcitonin  Dry lipid hydration  20  (Takeuchi et al 2003, 2005;
      Thongborisute et al 2006)
Enkephalin Double  emulsiﬁ  cation  50–85  (Ye et al 2000)
Epidermal growth factor receptor  Freeze-thawing extrusion  20–30  (Kullberg et al 2005)
Haptides -  ∼100  (Gorodetsky et al 2004)
Hemoglobin  Dry lipid hydration extrusion  37–62  (Ariﬁ  n and Palmer 2003;
      Patton and Palmer 2005;
      Teiji et al 2005; Xi and
     Guo,  in  press)
Horseadish peroxidase  Extrusion  2–5  (Visser et al 2005)
Human gamma-globulin  Dehydration-rehydration  30–31  (García-Santana et al 2006)
Insulin  Reverse phase  30–82  (Zhang et al
  evaporation    2005; Goto et al 2006)
 Freezing-thawing   
Leishmania antigen  Freeze-thawing extrusion  -  (Badiee et al 2007)
Leridistim Double  emulsiﬁ  cation  70  (Langston et al 2003)
Leuprolide  Dry lipid hydration  37–76  (Guo et al 2003;
  Reverse phase  33–72  Arulsudar et al 2004;
  evaporation    Shahiwala and Misra 2005;
      Carafa et al 2006)
Nerve growth factor  Reverse phase  24–34  (Xie et al 2005)
 evaporation   
Octreotide Double  emulsiﬁ  cation  50–85  (Ye et al 2000)
Progenipoietin Double  emulsiﬁ  cation  80–90  (Ramprasad et al 2003)
Recombinant malaria protein antigens  -  -  (Amselem et al 1992)
    
Superoxide dismutase  Dry lipid hydration  1–13  (Ruzica et al 2002)
 Dehydration-rehydration  2–3 
 Pro-liposome  39–65 
TATa peptide  Extrusion  -  (Torchilin et al 2001)
aTransactivating transcriptional activator.International Journal of Nanomedicine 2007:2(4) 601
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it is then thawed at a temperature above Tm. The vesicle 
suspension may undergo certain physicochemical changes 
thereby often equilibrating the internal and external aqueous 
phases of the vesicles, resulting in an increased association 
efficiency and possibly leading to the formation of an 
increased population of multivesicular vesicles (MVV) and 
to an elimination by means of fusion processes of very small 
vesicles eventually present. Typically, freezing-thawing 
cycles are repeated 3 to 6 times (Luo et al 2003; Kullberg 
et al 2005; Badiee et al 2007).
During the sonication method, MLV are treated, for 
a long period, with a probe type or bath type sonicator 
above the Tm under an inert atmosphere (usually nitrogen 
or argon) which leads to the defragmentation of MLV into 
small (sonicated) unilamellar vesicles (SUV) of diameters 
usually below 50 nm. The size of the SUV depends mainly 
on the sonication conditions and on the vesicle membrane 
composition (eg, cholesterol content).
In the dehydration-rehydration method, dehydrating 
preformed vesicles followed by a controlled rehydration 
above the Tm leads to the fusion of small preformed vesicles, 
resulting in multilamellar vesicles with high association 
efﬁ  ciency. After rehydration, the new vesicles formed are 
considerably larger than the initially present SUV and MLV 
(García-Santana et al 2006).
In reverse-phase evaporation method, a water-immiscible 
organic solvent of low boiling point is used in which the 
vesicle-forming amphiphiles are soluble, eg, diethyl ether, 
isopropyl ether, or mixtures of these ethers with chloroform 
or methanol. The amphiphiles are ﬁ  rst dissolved in the 
solvent, possibly with the help of chloroform or methanol 
if the solubility is too low. After adding the aqueous peptide 
or protein solution, the system is vortexed and brieﬂ  y 
sonicated in a bath-type sonicator until a relatively stable 
(reverse) emulsion is formed. On the removal of solvent 
under reduced pressure, the reverse emulsion transforms 
into an aqueous vesicle dispersion, which contains a 
considerable amount of the originally present peptide or 
protein entrapped within the vesicles. The association 
efﬁ  ciency obtained with this procedure is usually rather 
high (Xie et al 2005).
In the so-called ‘pro-liposome’ method, an initial mixture 
containing vesicle-forming amphiphiles, ethanol and water, is 
converted into vesicles by a simple dilution step (Walde and 
Ichikawa 2001; Anne 2002; Segota and Tezak 2006).
The double emulsification procedure involves the 
formation of a simple w/o emulsion. This ﬁ  rst emulsion 
is then mixed with a second aqueous solution to form a 
multiple w/o/w emulsion (Ye et al 2000; Langston et al 2003; 
Ramprasad et al 2003; Dai et al 2006).
Lipid nanoparticles
Solid lipid nanoparticles
For the location of drugs into SLN, the literature describes 
three different models according to Müller, Mader et al 
(2000) and Mehnert and Mader (2001): (i) the homogeneous 
matrix model, (ii) the drug-enriched shell model, and (iii) the 
drug-enriched core model. The morphological differences 
between those models depend mainly on the composition of 
the formulation itself, ie, the chemical nature of the bioac-
tive, lipid, and surfactant, as well as on the production (Souto 
2005). The matrix model is deﬁ  ned as a homogeneous lipid 
matrix with molecularily dispersed drug or drug being present 
in amorphous clusters. It is described for SLN prepared by 
the cold high pressure homogenization (HPH, described 
below) technique or when incorporating very lipophilic drugs 
in SLN when applying the hot HPH technique. When using 
the cold HPH, the bulk lipid contains the dissolved drug in 
molecularly dispersed form. Mechanical breaking of solid 
milled, drug-loaded bulk lipid by HPH leads to nanoparticles 
having the homogeneous matrix structure. The same will 
happen when the oil droplets produced by the hot HPH are 
cooled, crystallize, and no phase separation between lipid 
and drug occurs. This model is assumed for entrapped drugs 
that can show prolonged release from SLN (Muller, Mader 
et al 2000). The drug-enriched shell model is described 
by an outer shell enriched with drug, which covers a lipid 
core. This model is obtained when phase separation occurs 
during the cooling process from the liquid oil droplet to the 
formation of SLN when applying the hot HPH. The lipid 
precipitates ﬁ  rst forming an almost drug-free lipid core. 
At the same time, the concentration of active compound in 
the remaining liquid lipid increases continuously. Finally, 
the compound-enriched shell crystallizes. Once the drug 
molecules are enriched in the outer shell of the particles, this 
model is assumed for drugs that release very fast from SLN. 
The drug-enriched core model is formed when the opposite 
mechanism as described for the former model occurs. In this 
case, the drug precipitates ﬁ  rst and the lipid shell formed 
around this core will have distinctly less drug. This leads to 
a membrane-controlled release governed by Fick’s law of 
diffusion (Muller et al 2002a). This model is formed when the 
drug concentration is close to its saturation solubility in the 
melted lipid. It has been reported that drugs can also be linked 
with the outer layer of SLN composed of phospholipids and 
steric stabilizers. Distribution of the drug depends both on International Journal of Nanomedicine 2007:2(4) 602
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its physicochemical characteristics and on the components 
of the SLN. It is, however, most inﬂ  uenced by the partition 
coefﬁ  cient of the drug molecules (Cavalli et al 1999; Souto 
and Muller 2006). Examples of peptides and proteins associ-
ated to SLN are summarized in Table 2.
The literature describes four main methods for the incor-
poration of peptides and proteins into SLN. The HPH can be 
performed at elevated temperature (hot HPH technique) or 
at or below room temperature (cold HPH technique) (Zara 
et al 1999; Fundaro et al 2000; Miglietta et al 2000; Muller 
et al 2002a, 2002b). The particle size is decreased by cavita-
tion and turbulences. For the hot HPH, the lipid is heated at 
approx. 5–10ºC above its melting point, and further added 
the bioactive to this melted lipid phase. This mixture is then 
combined with an aqueous surfactant solution heated at the 
same temperature. A hot pre-emulsion is formed by high 
speed stirring. This hot pre-emulsion is converted into a 
nanoemulsion when processed in a temperature controlled 
high pressure homogenizer, generally applying between 3 to 
5 cycles at 500 bar. The obtained nanoemulsion recrystal-
lizes upon cooling down to room temperature forming SLN 
(Carsten et al 2004). The cold HPH is a suitable technique 
for processing temperature labile drugs or hydrophilic 
drugs. Here, the lipid and drug are melted together and then 
rapidly ground under liquid nitrogen forming solid lipid 
microparticles. A pre-suspension is formed by high speed 
stirring of the particles in a cold aqueous surfactant solution. 
This pre-suspension is then homogenized at or below room 
temperature forming SLN, the homogenizing conditions are 
generally 5 cycles at 500 to 800 bar (Almeida et al 1997).
In the solvent diffusion method, the lipid is ﬁ  rst dissolved 
in an organic phase, such as ethanol and acetone, using a 
water bath at 50 ºC. An acidic aqueous phase is required in 
order to adjust the zeta potential to induce lipid coacervation, 
which leads to formation of SLN. The particles are then easily 
separated by centrifugation (Hu et al 2002).
In the w/o/w double emulsion method, the hydrophilic 
drug is encapsulated, along with a stabilizer to prevent 
drug partitioning to the external water phase during solvent 
evaporation, in the internal water phase of a w/o/w double 
emulsion (García-Fuentes et al 2002; Garcia-Fuentes, Prego 
et al 2005; Garcia-Fuentes, Torres et al 2005; Trotta et al 
2006; Zhang et al 2006).
The group of Gasco has developed and optimized a suit-
able method for the preparation of SLN via microemulsions, 
which has been adapted and/or modiﬁ  ed by different labs 
(Schwarz and Mehnert 1999; Fundaro et al 2000; Hossain 
et al 2000; Igartua et al 2002). Firstly, a warm microemulsion 
is prepared by stirring, containing typically 10% of melted 
solid lipid, 15% of surfactant and up to 10% of co-surfactant. 
This warm microemulsion is then dispersed under stirring 
in excess cold water at approx. 2 to 3 ºC (typical ratio 1:50) 
using an especially developed thermostated syringe. The 
excess of water is removed either by ultra-ﬁ  ltration or by 
lyophilization in order to increase the particle concentration 
(Wissing et al 2004; Pedersen et al 2006).
Nanostructured lipid carriers
As mentioned before, the main difference between SLN 
and NLC is the fact the concept of the latter is performed by 
Table 2 Examples of peptides and proteins associated to SLN, the production procedure and the association efﬁ  ciency
Protein/peptide Production  procedure  Association  References
   efﬁ  ciency (%)
Bovine serum albumin  Hot HPHa technique  ∼100  (Gualbert et al 2003;
  Microemulsion technique    Schubert and Muller-Goymann
      2005; Pedersen et al 2006)
Calcitonin  w/o/w double emulsion  75–90  (Garcia-Fuentes, Prego et al 2005;
      Garcia-Fuentes, Torres et al 2005)
Cyclosporine A  Microemulsion technique  6.0–13 96  (Muller et al 2002a, 2006;
  Hot HPH technique    Ugazio et al 2002)
Gonadorelin  Solvent diffusion  50–69  (Hu et al 2004)
Human recombinant EPGb  Microemulsion technique  -  (Pedersen et al 2006)
Insulin  w/o/w double emulsion  27–68 35–45  (García-Fuentes et al 2002;
      Trotta et al 2006; Zhang et al 2006)
Lysozime  Cold HPH technique  ∼100  (Almeida et al 1997)
Streptavidin Microemulsion  technique  ∼100  (Pedersen et al 2006)
TATc peptide  Hot HPH technique  -  (Carsten et al 2004)
Thymopentin  Microemulsion technique  2–5  (Morel et al 1996)
aHigh Pressure Homogenization; bEpidermal Growth Factor; cTransactivating Transcriptional Activator.International Journal of Nanomedicine 2007:2(4) 603
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nanostructuring the lipid matrix, to increase the drug loading 
and to prevent drug expulsion. This could be realized in three 
ways: (i) the imperfect type, (ii) the multiple type, and (iii) 
the amorphous type.
Spatially different lipids, eg, acylglycerols composed of 
different fatty acids are mixed. Using spatially different lipids 
leads to larger distances between the fatty acid chains of the 
acylglycerols and general imperfections in the crystal and 
thus to more room for the accommodation of the drugs. The 
highest drug load could be achieved by mixing solid lipids 
with small amounts of liquid lipids. This model is called the 
imperfect type.
If higher amounts of oil are mixed with the solid lipid, a 
different type of nanostructure is present. Here, the solubility 
of the oil molecules in the solid lipid is exceeded; this leads to 
phase separation and the formation of oily nanocompartments 
within the solid lipid matrix (Jenning, Mader et al 2000; 
Jenning, Thunemann et al 2000; Jenning and Gohala 2001). 
Many drugs show a higher solubility in oils than in solid 
lipids so that they can be dissolved in the oil and still be 
protected from degradation by the surrounding solid lipids. 
This type of NLC is called the multiple type, and can be 
regarded as an analogue to w/o/w emulsions since it is an 
oil-in-solid lipid-in-water dispersion.
Since drug expulsion is caused by ongoing crystallization 
or transformation of the solid lipid, this can be minimized by 
the formation of a third type, the amorphous type. Here, the 
particles are solid but crystallization upon cooling is avoided 
by mixing special lipids (eg, hydroxyoctacosanylhydroxy-
stearate and isopropylmyristate) (Jenning, Mader et al 2000; 
Jenning, Thunemann et al 2000; Wissing et al 2004).
The methods used to produce NLC for peptide and protein 
are the above described w/o/w double emulsion, and the hot 
HPH technique. Examples of bioactives associated to NLC 
for oral delivery are the calcitonin and cyclosporine A. NLC 
for the delivery of calcitonin have been produced by w/o/w 
double emulsion, resulting an association efﬁ  ciency higher 
than 90% (Garcia-Fuentes, Prego et al 2005; Garcia-Fuentes, 
Torres et al 2005). NLC with cyclosporine A have been 
produced by hot HPH (Muller et al 2002a).
Toxicological concerns
One can anticipate that lipid-based colloidal carriers are well 
tolerated in living systems because they are made of physi-
ological compounds and therefore, metabolic pathways exist 
decreasing the risk of acute and chronic toxicity. Of course, 
the toxicity of the emulsiﬁ  ers has to be considered (Mehnert 
and Mader 2001).
Lipid carriers prepared with several lipids and emulsifying 
agents did not exhibit any cytotoxic effects in vitro up to 
concentrations of 2.5% lipid (Muller et al 2005). In fact, 
it has been shown that even concentrations higher than 
10% of lipid phase led to a viability of 80% with human 
granulocytes in culture (Muller et al 1996). For comparison, 
PLA nanoparticles showed complete cell death at 0.5%. The 
low toxicity of lipid nanoparticles has already been shown 
in human promyelotic cells (HL60) (Garcia-Fuentes, Prego 
et al 2005; Muller et al 2005).
It can be assumed that the cytotoxicity of the SLN can 
be mainly attributed to components of the aqueous phase, 
especially to non-ionic emulsiﬁ  ers and preservatives that 
have eventually been used (Schubert and Muller-Goymann 
2005).
Considering a future application of these systems for 
peptide or protein delivery, for most biomacromolecules 
a parenteral application is inevitable. For that reason, the 
cytotoxicity of liposomes and lipid nanoparticles is an essen-
tial product parameter with regard to a prospective in vivo 
tolerance evaluation in humans and/or animals. Most studies 
have been conducted with acylglycerols composed of fatty 
acids and lecithins, which are mostly accepted as safe. Good 
tolerability depends in the ﬁ  rst line on the used surfactant and 
secondarily on the lipid. To formulate parental lipid-based 
carriers, surfactant of GRAS status must be employed, eg, 
lecithin, Tween 80, Poloxamer 188, Span 85, and sodium 
glycocholate. When performing bolus injections into mice 
good tolerability was found for most of these surfactants 
coating SLN (Wissing et al 2004). As described, for cetyl 
palmitate SLN with different surfactants no acute toxicity 
and no increase in liver and spleen weight was observed. 
After autopsy and histopathology no signiﬁ  cant evidence 
was documented that SLN were acute toxic to tested animals 
(Wissing et al 2004).
No problems should be observed for peroral or trans-
dermal administration and intramuscular or subcutaneous 
injection if appropriate surfactants are used. The particle size 
is not a very critical issue for these administration routes, 
because a low content of microparticles might decrease the 
performance of the colloidal system, but will not cause toxic 
events. Size is relevant if such formulations are intended 
for intravenous administration. In this case toxicological 
problems may arise if size is not controlled. Injections of 
highly polydispersed particle dispersions can cause embo-
lism due to the risk of particle aggregation during injection. 
When particle dispersions are intended for intravenous 
administration production of monodispersed formulations International Journal of Nanomedicine 2007:2(4) 604
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must be guaranteed. Moreover, colloidal carriers can be 
coated with hidrophilic polymers or albumin to actively 
target the incorporated drugs to specific cells, tumors 
and/or organs. This strategy can be successfully applied to 
concentrate drugs in such target tissues minimizing systemic 
side effects and therefore toxicity. The absence of pyrogens 
must be checked for parenteral administration. Problems 
may arise, because colloidal carriers may interfere with the 
pyrogens causing gelation of the suspension, which could 
result in embolism.
Conclusions
In the future we can expect an increasing number of 
therapeutic molecules such as proteins, oligonucleotides and 
DNA as vaccine or as drug for gene therapy. The employment 
of lipid-based carriers has been found to be suitable for the 
administration of peptides and proteins through different 
routes.
Liposomes have been used successfully in the ﬁ  eld 
of biology, biochemistry and medicine since its origin 
(Bangham et al 1965). It exhibits a number of advantages in 
terms of amphiphilic character. Biocompatibility, and ease of 
surface modiﬁ  cation rendering it a suitable candidate delivery 
system for peptides and proteins molecules.
Once lipid nanoparticles are a new and innovative 
therapeutic delivery system, we can expect in the future 
an increasing number of contributions describing delivery 
of recombinant proteins (Wissing et al 2004). Lipid 
nanoparticles, particularly, NLC are a promising approach for 
the formulation of peptides and proteins with poor aqueous 
solubility. Since nearly 40% of the new drug compounds 
are hydrophobic, it appears that more drug products will 
be formulated as NLC for the pharmaceutical market in the 
very near future.
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